Carman Alenson Biography and Net Worth

Insider of Agios Pharmaceuticals

Currently, Carman Alenson is Vice President-Accounting, Treasury & Tax at Agios Pharmaceuticals, Inc.

She received an MBA and an undergraduate degree from Boston University.

What is Carman Alenson's net worth?: The estimated net worth of Carman Alenson is at least $48,689.80 as of June 21st, 2021. Ms. Alenson owns 1,777 shares of Agios Pharmaceuticals stock worth more than $48,690 as of April 2nd. This net worth estimate does not reflect any other investments that Ms. Alenson may own. Learn More about Carman Alenson's net worth.
How do I contact Carman Alenson?: The corporate mailing address for Ms. Alenson and other Agios Pharmaceuticals executives is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. Agios Pharmaceuticals can also be reached via phone at (617) 649-8600 and via email at investors@agios.com. Learn More on Carman Alenson's contact information.
Has Carman Alenson been buying or selling shares of Agios Pharmaceuticals?: Carman Alenson has not been actively trading shares of Agios Pharmaceuticals during the last ninety days. Most recently, Carman Alenson sold 1,777 shares of the business's stock in a transaction on Monday, June 21st. The shares were sold at an average price of $61.61, for a transaction totalling $109,480.97. Following the completion of the sale, the insider now directly owns 1,777 shares of the company's stock, valued at $109,480.97. Learn More on Carman Alenson's trading history.
Who are Agios Pharmaceuticals' active insiders?: Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), Tsveta Milanova (Chief Commercial Officer), Darrin Miles (Insider), and David Scadden (Director). Learn More on Agios Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Agios Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 24,428 shares worth more than $912,905.28. The most recent insider tranaction occured on January, 6th when insider Tsveta Milanova sold 2,804 shares worth more than $90,232.72. Insiders at Agios Pharmaceuticals own 4.9% of the company. Learn More about insider trades at Agios Pharmaceuticals.
Information on this page was last updated on 1/6/2025.

Carman Alenson Insider Trading History at Agios Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/21/2021	Sell	1,777	$61.61	$109,480.97	1,777
4/15/2021	Sell	991	$54.00	$53,514.00
9/2/2020	Sell	250	$39.93	$9,982.50	184
12/26/2019	Sell	2,950	$50.09	$147,765.50
7/9/2018	Sell	272	$84.94	$23,103.68	272
1/12/2018	Sell	2,150	$75.00	$161,250.00	2,150

Carman Alenson Buying and Selling Activity at Agios Pharmaceuticals

Agios Pharmaceuticals Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $27.40

$26.66

$29.35

50 Day Range

MA: $32.99

$27.40

$35.54

2 Week Range

Now: $27.40

$26.66

$62.58

Volume

936,690 shs

Average Volume

703,492 shs

Market Capitalization

$1.57 billion

P/E Ratio

2.42

Dividend Yield

N/A

Beta

0.9